Business
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific SessionsBiomea to hold an investor and
About this update from Biomea Fusion, Inc.
[{"type":"text","content":"New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific SessionsBiomea to hold an investor and KOL event during the Scientific Sessions REDWOOD CITY, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it will present new clinical data from the ongoing Phase II portion of its COVALENT-111 trial, which is evaluating BMF-219 as a treatment for patients with type 2 diabetes, in a late-breaking poster presentation at the 2023 American Diabetes Association (ADA) 83rd Scientific Sessions, to be held June 23 – 26, 2023 in San Diego, CA. The company will also host an investor and KOL event during the Scientific Session. Biomea will disclose additional information about the late-breaking presentation in accordance with ADA’s abstract embargo policies. In addition, the company will provide further details on the investor and KOL event at a later date. The loss of insulin-producing beta cells is a root biological cause of type 2 diabetes and its progression. BMF-219, a novel covalent menin inhibitor, is designed to regenerate, preserve, and reactivate healthy, insulin-producing beta cells, thereby normalizing glycemic control and halting or reversing type 2 diabetes disease progression. Biomea is evaluating BMF-219’s potentially novel mechanism of action with an intended treatment goal of re-establishing a pool of healthy beta cells, which may allow for continued glycemic control for prolonged periods even after treatment is stopped. COVALENT-111 COVALENT-111 is a multi-site, randomized, double-blind, placebo-controlled Phase I/II study. In the completed Phase I portion of the trial, healthy volunteers were enrolled in single ascending dose cohorts to ensure safety at the prospective dosing levels for patients with type 2 diabetes. Phase II consists of multiple ascending dose cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies. Additional information about the Phase I/II clinical trial of BMF-219 in type 2 diabetes can be found at ClinicalTrials.gov using the identifier NCT...